Sernova (TSE:SVA) Trading 5.3% Higher - Still a Buy?

Key Points

• Sernova Corp. (TSE:SVA) shares rose by 5.3% during trading, reaching a price of C$0.20, with increased trading volume of approximately 189,238 shares.
• The company operates in the regenerative medicine sector, developing bio-hybrid organs that integrate living cells with non-living materials to enhance organ function.
• Sernova has a market capitalization of C$67.30 million and a concerning price-to-earnings ratio of -1.93, indicating potential financial challenges.

Sernova Corp. (TSE:SVA - Get Free Report)'s share price shot up 5.3% on Wednesday . The stock traded as high as C$0.20 and last traded at C$0.20. 189,238 shares were traded during trading, an increase of 38% from the average session volume of 136,995 shares. The stock had previously closed at C$0.19.

Sernova Trading Down 2.5%

The company's fifty day moving average is C$0.17 and its 200-day moving average is C$0.18. The stock has a market cap of C$65.62 million, a PE ratio of -1.88 and a beta of 1.35. The company has a debt-to-equity ratio of -4.40, a current ratio of 0.32 and a quick ratio of 18.11.

Sernova Company Profile

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues.